Drugs that contain Azelastine Hydrochloride; Fluticasone Propionate

1. List of Dymista drug patents

DYMISTA's oppositions filed in EPO
DYMISTA Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9901585 MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration
Jun, 2023

(2 months from now)

US9259428 MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration
Jun, 2023

(2 months from now)

US8163723 MYLAN SPECIALITY LP Combination of azelastine and steroids
Aug, 2023

(5 months from now)

US9259428

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration
Dec, 2023

(8 months from now)

US8163723

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and steroids
Feb, 2024

(11 months from now)

US8168620 MYLAN SPECIALITY LP Combination of azelastine and steroids
Feb, 2026

(2 years from now)

US8168620

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and steroids
Aug, 2026

(3 years from now)

Market Authorisation Date: 01 May, 2012

Treatment: Treatment of seasonal allergic rhinitis; Treatment of allergic rhinitis, including seasonal allergic rhinitis; Allergic rhinitis; Treatment of symptoms of seasonal allergic rhinitis; Relief of symptoms associated with seasonal allergic rhinitis

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of DYMISTA before it's patent expiration?
More Information on Dosage

DYMISTA family patents

10

United States

4

Brazil

3

Portugal

3

Spain

3

Korea, Republic of

3

Canada

3

Cyprus

3

Slovenia

3

Israel

3

Australia

3

Denmark

3

European Union

2

United Kingdom

2

New Zealand

2

Hungary

1

Germany

1

Russia

1

Costa Rica

1

Mexico

1

Austria

1

Morocco

1

China

1

Tunisia

1

South Africa

1

Luxembourg

1

Poland

1

Georgia

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic